Changes in the governance of NFL Biosciences
27 Février 2023 - 5:45PM
Changes in the governance of NFL Biosciences
Changes in the governance of NFL Biosciences
NFL BIOSCIENCES (Euronext Growth Paris -
FR0014003XT0 - ALNFL), a biopharmaceutical company developing
botanical drugs for the treatment of addictions, and in particular
NFL-101, its drug candidate for smoking cessation, announces the
appointment of Ignacio Faus, current CEO, as Chairman of the Board
of Directors.
Appointment of Dr. Ignacio Faus as
Chairman of the Board of Directors
At its meeting on February 27, 2023, the Board
of Directors of NFL Biosciences acknowledged the wish of Mr. Joël
Besse to step down as Chairman and member of the Board of Directors
in order to fully devote himself to his activity as investor in
unlisted startup companies in the life sciences sector.
Dr. Ignacio Faus, currently Director and Chief
Executive Officer of NFL Biosciences, has been appointed Chairman
of the Board of Directors and now becomes Chairman and Chief
Executive Officer, replacing Mr. Joël Besse. Having joined NFL
Biosciences in 2019 as an investor, Dr. Ignacio Faus joined the
management team in early 2021. He has 27 years of experience in
large and medium-sized pharmaceutical companies and in private and
public biotech companies: Bristol Myers Squibb, Grupo Uriach,
Ferrer and co-founder in 2006 and CEO of Palau Pharma (divested in
2013). In recent years, Ignacio Faus has also been a Director of
several private and public biotech companies as well as private
equity funds in Europe and the United States. He holds a PhD in
Biochemistry (Indiana University, USA) and an MBA in
Entrepreneurship and Finance from the Kellogg School of Management
(Northwestern University, USA).
Ignacio Faus, Chairman
and CEO of NFL Biosciences,
commented: “I am very honored to take
over as Chairman of the Board of NFL Biosciences and would like to
sincerely thank Joël Besse for his operational and financial
involvement since 2018. After his support during the IPO, the
company now has a secure financial position for the next 18 months,
following the recently concluded capital increase and the financing
from Bpifrance.”
About NFL
Biosciences
NFL Biosciences is a biopharmaceutical company
based in the Montpellier area which develops botanical drug
candidates for the treatment of addictions. NFL Biosciences'
ambition is to bring new, natural, safer and more effective
therapeutic solutions to the entire world population, including
low- and middle-income countries. Its most advanced product, called
NFL-101, is a standardized, nicotine free tobacco leaf extract
protected by two patent families. NFL Biosciences intends to offer
smokers who want to quit a natural, safe, easy-to-administer and
personalized alternative. NFL Biosciences is also developing
NFL-301, a natural drug candidate for the reduction of alcohol
consumption and has a drug development project for the treatment of
cannabis use disorders.
The shares of NFL Biosciences are listed on
Euronext Growth Paris (FR0014003XT0 – ALNFL). Find out more at
www.nflbiosciences.com
Contacts
Bruno Lafont – info@nflbiosciences.com - +33 4
11 93 76 67 Agence
Calyptus – nflbio@calyptus.net - +33 1 53 65 68 68
- NFLBiosciences_CP_Gouvernance_ENG
NFL Biosciences (EU:ALNFL)
Graphique Historique de l'Action
De Août 2024 à Sept 2024
NFL Biosciences (EU:ALNFL)
Graphique Historique de l'Action
De Sept 2023 à Sept 2024